Leading the Way in Life Science Technologies

GEN Exclusives

More »

Best of the Web

More »
Apr 15, 2009 (Vol. 29, No. 8)

Broad Institute of MIT and Harvard

  • “Broad” coverage
  • Nothing significant
In 2003, Eli and Edythe Broad, recognizing the promise of genomics to change medicine, founded the institute at MIT/ Harvard that bears their name. Broadly organized, the institute has programs for cancer, genome biology, cell circuits, psychiatry, metabolic disease, popular genetics, chemical biology, infectious disease, and computational biology. Whew! Combine that with excellent coverage of news, links to enormous data sets, extensive programs for outreach, and a section relating to careers in the field and you’ve got an institute that is not only on the cutting edge of modern biology, but a superb website supporting its efforts. There’s even something for software junkies, with downloadable applications for handling/analyzing genomic sequences, genetic variation, linkages, gene expression, and more. A great site and a great program. Definitely worth a look.
  • Key:
  • Strong Points
  • Weak Points
  • Ratings:
  • Excellent
  • Very Good
  • Good

*The opinions expressed are solely those of the author(s) and should not be construed as reflecting the viewpoints of the publisher, Genetic Engineering & Biotechnology News, Mary Ann Liebert, Inc., the publishing house, or employees and affiliates thereof.

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »